Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Design and Characterization of a TROP2-Targeting Non-Cleavable ADC with Enhanced Antitumor Activity

Simmyung Yook – Professor, Sungkyunkwan University, College of Pharmacy

    Poster Presenter(s)

  • Yulim Shin, B.S.

    Graduate Student
    Sungkyunkwan University School, Republic of Korea

Introduction:

TROP2 is a tumor-associated transmembrane glycoprotein overexpressed in many cancers and promotes malignant growth. TROP2-targeting antibody–drug conjugates (ADCs) enable selective delivery of potent cytotoxic agents to TROP2-positive tumors with minimal off-target toxicity. In this study, we developed a TROP2-targeting ADC using a non-cleavable SMCC linker and the microtubule inhibitor DM1, distinct from clinically approved TROP2 ADCs that mainly employ topoisomerase I inhibitors. We evaluated its physicochemical properties, in vitro antitumor activity, and cellular internalization.

Learning Objectives:

  • Understand the difference between our Trop2 ADCs and existing TROP2-targeting ADCs regarding drug and linker.
  • Evaluate how TROP2 expression level influences the in vitro cytotoxicity and internalization behavior of TROP2 ADC.
  • Integrate analytical characterization and cell based assays to assess TROP2 antibody drug conjugate performance.